Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents.
EPR effect
PDT
carbon monoxide
nanomedicine
nanoprobe
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
16 Jul 2019
16 Jul 2019
Historique:
received:
14
06
2019
revised:
11
07
2019
accepted:
12
07
2019
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
epublish
Résumé
One obstacle to the successful delivery of nanodrugs into solid tumors is the heterogeneity of an enhanced permeability and retention (EPR) effect as a result of occluded or embolized tumor blood vessels. Therefore, the augmentation of the EPR effect is critical for satisfactory anticancer nanomedicine. In this study, we focused on one vascular mediator involved in the EPR effect, carbon monoxide (CO), and utilized two CO generating agents, one is an extrinsic CO donor (SMA/CORM2 micelle) and another is an inducer of endogenous CO generation via heme oxygenase-1 (HO-1) induction that is carried out using pegylated hemin. Both agents generated CO selectively in solid tumors, which resulted in an enhanced EPR effect and a two- to three-folds increased tumor accumulation of nanodrugs. An increase in drug accumulation in the normal tissue did not occur with the treatment of CO generators. In vivo imaging also clearly indicated a more intensified fluorescence of macromolecular nanoprobe in solid tumors when combined with these CO generators. Consequently, the combination of CO generators with anticancer nanodrugs resulted in an increased anticancer effect in the different transplanted solid tumor models. These findings strongly warrant the potential application of these CO generators as EPR enhancers in order to enhance tumor detection and therapy using nanodrugs.
Identifiants
pubmed: 31315251
pii: pharmaceutics11070343
doi: 10.3390/pharmaceutics11070343
pmc: PMC6680399
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 29400001, JP25430162, JP16K08217
Organisme : Ministerstvo Vnitra České Republiky
ID : 16-28594A
Références
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):115-21
pubmed: 11820286
Int Immunopharmacol. 2003 Mar;3(3):319-28
pubmed: 12639809
Apoptosis. 2004 Jan;9(1):27-35
pubmed: 14739596
Cancer Res. 2006 Jul 1;66(13):6732-40
pubmed: 16818648
Pharmacol Rev. 2008 Mar;60(1):79-127
pubmed: 18323402
Cancer Sci. 2009 Dec;100(12):2426-30
pubmed: 19793083
Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5
pubmed: 20304019
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
Nat Rev Drug Discov. 2010 Sep;9(9):728-43
pubmed: 20811383
Nat Mater. 2011 Jun 19;10(7):545-52
pubmed: 21685903
J Pharmacol Exp Ther. 2011 Dec;339(3):779-89
pubmed: 21890508
Cancer Sci. 2012 Mar;103(3):535-41
pubmed: 22145952
Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(3):53-71
pubmed: 22450535
J Control Release. 2012 Dec 10;164(2):138-44
pubmed: 22595146
Nat Rev Clin Oncol. 2012 Jul 10;9(8):437-49
pubmed: 22777060
J Control Release. 2012 Dec 10;164(2):108-14
pubmed: 22800574
Cancer Sci. 2013 Jul;104(7):779-89
pubmed: 23495730
Cancer Res. 2013 Dec 1;73(23):7009-21
pubmed: 24121491
J Control Release. 2014 Jan 28;174:81-7
pubmed: 24269967
J Control Release. 2014 Sep 28;190:371-80
pubmed: 24818766
J Control Release. 2014 Aug 10;187:14-21
pubmed: 24852097
J Pharm Sci. 2014 Oct;103(10):3235-43
pubmed: 25041982
Adv Drug Deliv Rev. 2015 Aug 30;91:3-6
pubmed: 25579058
Microcirculation. 2016 Apr;23(3):173-82
pubmed: 26237291
J Control Release. 2015 Nov 10;217:1-9
pubmed: 26302904
Oncotarget. 2016 Apr 26;7(17):23919-32
pubmed: 26993595
J Drug Target. 2017 Nov - Dec;25(9-10):781-785
pubmed: 28988499
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Eur J Pharm Biopharm. 2018 Sep;130:165-176
pubmed: 29885851
Medchemcomm. 2016 Dec 21;8(2):415-421
pubmed: 30108759
Mol Cancer Ther. 2018 Dec;17(12):2643-2653
pubmed: 30232144
Blood. 2019 Feb 21;133(8):781-789
pubmed: 30578253
Cancers (Basel). 2019 Jan 16;11(1):null
pubmed: 30654498
Bioconjug Chem. 2019 May 15;30(5):1323-1330
pubmed: 30848886
Cancer Surv. 1993;17:315-41
pubmed: 8137346
Br J Cancer. 1997;75(5):650-5
pubmed: 9043019
Int J Cancer. 1997 Nov 14;73(4):607-12
pubmed: 9389579
Cancer Res. 1998 Jan 1;58(1):159-65
pubmed: 9426072
Anticancer Res. 1998 Jul-Aug;18(4A):2547-50
pubmed: 9703908